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Abstract 
Background: Based on some previous research, the chalcone derivatives exhibited potent xanthine oxidase inhibi-
tory activity, e.g. sappanchalcone (7), with IC50 value of 3.9 μM, was isolated from Caesalpinia sappan. Therefore, objec-
tives of this research are design and synthesis of 7 and other chalcone derivatives by Claisen–Schmidt condensation 
and then evaluate their XO inhibitory activity.
Results: Fifteen chalcone derivatives were synthesized by Claisen–Schmidt condensation, and were evaluated for 
XO inhibitory activity. Nine out of 15 synthetic chalcones showed inhibitory activity (3; 5–8; 10–13). Sappanchalcone 
derivatives (11) (IC50, 2.5 μM) and a novel chalcone (13) (IC50, 2.4 μM) displayed strong xanthine oxidase inhibitory 
activity that is comparable to allopurinol (IC50, 2.5 μM). The structure–activity relationship of these chalcone deriva-
tives was also presented.
Conclusions: It is the first research on synthesis sappanchalcone (7) by Claisen–Schmidt condensation. The overall 
yield of this procedure was 6.6 %, higher than that of reported procedure (4 %). Design, synthesis, and evaluation of 
chalcone derivatives were carried out. This result suggests that the chalcone derivative can be used as potential non-
purine XO inhibitors.
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Background
Xanthine oxidase (XO) is a key enzyme in purine meta-
bolic pathway. This complex metalloflavoprotein cata-
lyzes the oxidation of hypoxanthine into xanthine and 
then finally into uric acid (Massey et al. 1969). Overpro-
duction or under excretion of uric acid leads to hyper-
uricemia, a key cause of gout (Scott and Agudelo 2003). 
Also, hyperuricemia has been identified as an independ-
ent risk factor for chronic kidney and cardiovascular 
diseases (Edwards 2008; Nakagawa et  al. 2006); thus, 
maintaining uric acid at a normal level is an important 
therapy to prevent gout. In many kinds of research, XO 
has been targeted as a promising agent for treatment of 
hyperuricemia. Allopurinol is a potent XO inhibitor with 
a purine backbone and has been used clinically for more 
than 40  years (Murata et  al. 2009). Unfortunately, this 
drug has infrequent and severe side effects as in the cause 
of hypersensitivity syndrome (Hammer et al. 2001), Ste-
vens–Johnson syndrome (Fritsch and Sidoroff 2000), and 
renal toxicity (Horiuchi et al. 2000). Therefore, there is a 
need to develop other novel chemical structural types of 
XO inhibitors.
Chalcones are within a class of chemical compounds 
that widely exist in a variety of medicinal plants. Claisen–
Schmidt condensation, a base catalyzed condensation, 
was found to be most convenient to synthesize chalcones. 
Their flexible structure allows them to possess a large 
number of biological activities including antitumor, anti-
fungal, antiprotozoal, antimitotic, and antiviral (Zhang 
et al. 2013). Some chalcone derivatives exhibited potent 
XO inhibitory activity (Beiler and Martin 1951; Niu et al. 
2011).
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Our preliminary screening to search for XO inhibitory 
activity of Vietnamese medicinal plants revealed that the 
methanolic extract of Caesalpinia sappan’s heartwood 
exhibited significant XO inhibitory activity with an IC50 
value of 14.2  μg/mL (Nguyen et  al. 2005). The bioactiv-
ity-guided fractionation of MeOH extract of C. sappan’s 
heartwood was carried out. Sappanchalcone (7) was iso-
lated from EtOAc-soluble fraction (IC50, 12.8  μg/mL); 
this compound displayed the most potent activity with 
an IC50 value of 3.9 μM, comparable to that of allopurinol 
(IC50, 2.5 μM) (Nguyen et al. 2005). To study the possibil-
ity of using 7 as gout treatment required a large amount 
of this compound but the amount of 7 in C. sappan is 
very low.
The synthesis of 7 was carried out by Heck coupling 
reaction followed by demethylation (Bianco et al. 2004). 
Therefore, objectives of this research are design and syn-
thesis of 7 and other chalcone derivatives by Claisen–
Schmidt condensation and then evaluate their XO 
inhibitory activity.
Results and discussion
As outlined in Scheme  1, some known and novel chal-
cone analogs (group I: the hydroxyl groups attached to 
one of two aromatic rings of chalcones; and group II: 
both two aromatic rings carried the hydroxy groups) 
were prepared via Claisen Schmidt condensation reac-
tions between appropriate benzaldehydes and aryl 
methyl ketones. The reaction was monitored by thin-
layer chromatography (TLC). The reaction mixture after 
aldol condensation was acidified and cooled to obtain the 
crude product. Pure chalcone was purified by recrystal-
lization and structure elucidation was determined by 
NMR spectroscopy. The overall yield of the reaction was 
then measured by HPLC–UV/260 nm.
For the purpose of simplifying the synthesis, the 
protecting group was not carried out, so the con-
centration of aqueous alkaline base was critical in 
Claisen–Schmidt condensation. Therefore, typical reac-
tions affording 3,4-dihydroxychalcone (3) and 3,4,2ʹ,4ʹ-
tetrahydroxychalcone (5) were investigated in the 
presence of different concentrations of the aqueous solu-
tion of KOH at room temperature 30 °C (Table 1).
The synthesis of 3, in the presence of 1.00 mL of MeOH 
as the solvent, and aqueous base with different concentra-
tions from 6 to 14 M, together with ultrasound-assisted 
(UA), afforded the highest yield of 3 (39.7  %) when the 
reaction was carried out at KOH 10 M (Table 1, entry 3). 
When comparing the synthesis of 5 and that of 3, both 
were synthesized from 3,4-dihydroxybenzaldehyde (1a), 
differed only in acetophenone derivatives. In this case, 
we used 2ʹ,4ʹ-dihydroxyacetophenone (2b), a more polar 
substrate than acetophenone (2a). The use of MeOH 
solvent was not necessary because both substrates were 
dissolved in alkaline solution well; and highest yield of 5 
(33.4  %) was afforded when KOH 14  M (Table  1, entry 
10) was used.
From results in Tables 2 and 3, the yield of these typi-
cal reactions increased up to a period and then stopped 
changing. The reaction time may vary depending on dif-
ferent activation methods i.e. conventional heating (entry 
1–4 in Tables 2 or 3) or ultrasound-assisted (entry 5–11 
in Tables  2 or 3). The reaction temperature was signifi-
cantly impacted yield of the synthesis of 3 and 5; it can 
be seen that the optimal reaction temperatures were 


























Scheme 1 Synthesis of chalcones in group I and group II. Reagents and conditions: a KOHaq, MeOH, ultrasound-assisted; b KOHaq, ultrasound-
assisted
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respectively. Due to limited solubility in the aqueous base 
of acetophenone (2a), using a suitable organic solvent 
and appropriate volume is crucial to synthesize 3. There-
fore, under these optimal conditions, an investigation on 
the effect of volume of MeOH (Table 2, entry 13, 16–19) 
was carried out.
The molar ratio of two reactants (1a/2a or 1a/2b) was 
also investigated (Table 2, entry 13, 20–23; and Table 3, 
entry 14, 16–19). When the molar ratio of benzalde-
hyde and acetophenone derivatives was 2.5:1 or 3:1, the 
residual reactants and desired products crystallized 
simultaneously. So, the recrystallization was not be used 
to purify the crude product. Therefore, the molar ratio 
of two reactants of 2:1 was recommended in our case. 
From the above results, a set of conditions to synthesize 
the chalcone in group I [3,4-dihydroxychalcone (3) and 
2′,4′-dihydroxychalcone (4)] was proposed: reaction was 
carried out at KOH 10 M, under ultrasound-assisted for 
6 h at 70 °C, using 1.00 mL of MeOH as solvent and molar 
ratio of 1/2 = 2:1 (Table 2, entry 21). Moreover, that of 
the chalcone in group II [3,4,2ʹ,4ʹ-tetrahydroxychalcone 
(5) and 2,4,2′,4′-tetrahydroxychalcone (6)], as follows: 
reaction was carried out at KOH 14 M, under ultrasound-
assisted for 8  h at 80  °C, and molar ratio of 1/2 =  2: 1 
(Table 3, entry 17).
Sappanchalcone (7) was synthesized by the reac-
tion of 4ʹ-hydroxy-2ʹ-methoxyacetophenone (2c) with 
3,4-dihydroxybenzaldehyde (1a) (Scheme  2). However, 
4ʹ-hydroxy-2ʹ-methoxyacetophenone (2c) has not been 
yet widely commercialized. It was synthesized by the 
acetylation of 3-methoxyphenol and acetic acid in the 
presence of polyphosphoric acid (P2O5 > 85 %) as a cat-
alyst (Nagai et  al. 1984; Nakazawa 1954). However, this 
reaction also obtained two other by-products with sig-
nificant yield: 2ʹ-hydroxy-4ʹ-methoxyacetophenone (2d) 
and 3ʹ-acetyl-2ʹ-hydroxy-4ʹ-methoxyacetophenone (2e).
Compound 7, both two aromatic rings carried the 
hydroxy groups, so it was classified as group II. However, 
with above optimal conditions, the desired product was 
not observed. In compound 2c, the methoxyl group at 
position C(2ʹ) was less polar than hydroxyl group, then 
changed the reactivity of compound 2c comparing to 
compound 2b. Therefore, the KOH concentration was 
again investigated while other optimal parameters have 
remained the same as in the synthesis of chalcone in 
group II (Table 1, entry 12–15).
Bioactivity of chalcone depended largely on 
amount and properties of substituents on two phe-
nyl rings. Especially the hydroxyl groups were con-
sidered as key substituents that significantly enhance 
Table 1 Optimal condition for the concentration of KOH
a Synthesis of chalcone in group I: 1a/2a = 1/1; MeOH (1.00 mL); 30 °C; UA; 6 h
b Synthesis of chalcone in group II: 1a/2b = 1/1; H2O (1.00 mL); 30 °C; UA; 6 h
c Synthesis of 7: 1a/2c = 2/1; H2O (1.00 mL); 80 °C; UA; 8 h
d Using a solid KOH
















Table 2 Optimization of parameters for the synthesis of 3
Reaction was carried out at KOH 10 M
a Using CH
b Using UA








1a 30 6 1:1 1.00 24.1
2a 30 12 1:1 1.00 29.2
3a 30 18 1:1 1.00 36.2
4a 30 24 1:1 1.00 38.3
5b 30 2 1:1 1.00 24.7
6b 30 3 1:1 1.00 27.5
7b 30 4 1:1 1.00 29.0
8b 30 5 1:1 1.00 31.9
9b 30 6 1:1 1.00 38.0
10b 30 7 1:1 1.00 36.8
11b 30 8 1:1 1.00 36.1
12b 60 6 1:1 1.00 46.3
13b 70 6 1:1 1.00 52.1
14b 80 6 1:1 1.00 47.7
15b 90 6 1:1 1.00 45.1
16b 70 6 1:1 0.25 32.2
17b 70 6 1:1 0.50 40.8
18b 70 6 1:1 0.75 46.5
19b 70 6 1:1 1.50 51.5
20b 70 6 1.5:1 1.00 70.6
21b 70 6 2:1 1.00 77.3
22b 70 6 2.5:1 1.00 79.8
23b 70 6 3:1 1.00 81.6
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the activity of chalcone derivatives. Therefore, we car-
ried out the O-methylation and O-acetylation reac-
tions of some reactants and chalcones, to diversify 
the chalcone derivatives. For this purpose, (1) the 
O-methylation reaction on three substrates: 3,4-dihy-
droxybenzaldehyde (1a), 2,4-dihydroxybenzaldehyde (1c) 
and 2ʹ,4ʹ-dihydroxyacetophenone (2b); (2) the O-methyl-
ation reaction on two products: 3,4-dihydroxychalcone 
(3) and 3,4,2ʹ,4ʹ-tetrahydroxychalcone (5); and (3) the 
O-acetylation reaction on 3,4,2ʹ,4ʹ-tetrahydroxychalcone 
(5) were carried out. With these schemes, ten chal-
cone derivatives: 3,2ʹ,4ʹ-trihydroxy-4-methoxychalcone 
(8); 2ʹ,4ʹ-dihydroxy-3,4-dimethoxychalcone (9); 3,4,2ʹ 
-trihydroxy-4ʹ-methoxychalcone (10); 3,4-dihydroxy-2ʹ,4ʹ- 
dimethoxychalcone (11); 2,2 ,ʹ4ʹ-trihydroxy-4-methoxychalcone 
(12); 3ʹ-caffeoyl-3,4,2ʹ-trihydroxy-4ʹ-methoxychalcone 
(13); 3-hydroxy-4-methoxychalcone (14); 3,4-dimeth-
oxychalcone (15); 2ʹ-hydroxy-3,4,4ʹ-trimethoxychalcone 
(16); and 3,4,4ʹ-triacetoxy-2ʹ-hydroxychalcone (17) were 
obtained (Scheme  3). NMR data validated the forma-
tion of these chalcones  (Additional file  1). Moreover, 
two novel chalcones (13 and 17) were also identified by 
HRMS data (Additional file 1).
XO inhibitory activity of the synthetic chalcone deriv-
atives (3–17) and purchased chalcone (18) was exam-
ined by using allopurinol as a positive control. Among 
fifteen synthetic chalcones, nine compounds showed XO 
inhibitory activity with IC50 values <50  μM (Table  4). 
Four of these compounds displayed potent activity (5, 7, 
11 and 13 with IC50 values ranging from 2.4 to 4.3 μM), 
comparing to positive control, allopurinol (IC50, 2.5 μM). 
Compounds 6, 10 and 12 showed relatively strong inhib-
itory activity with IC50, 16.3, 19.2 and 21.8 μM, respec-
tively. Compounds 3 and 8 displayed average activity 
with IC50, 36.7 and 40.9 μM, respectively. Therefore, XO 
inhibitory activity of the chalcone derivatives depended 
on the location and number of the substituents on two 
phenyl rings.
Consequently, according to the above results, the 
structure–activity relationship of some synthetic chal-
cone derivatives (compound 3–18) was evaluated. In all 
cases, the carbonyl group plays a major role in the XO 
inhibition activity of these compounds; it acts as a reac-
tive oxygen species acceptor (Ponce et  al. 2000). Like-
wise, the presence of hydroxyl groups composes another 
important bioactive region. That are mainly involved in 
dispersion interactions with an aromatic aminoacidic 
residue of the enzyme (Costantino et  al. 1996). So, the 
activity of chalcones increases with increasing numbers 
of hydroxyls. The tetrahydroxychalcones (5, 6) are more 
active than either of the dihydroxychalcones (3, 4); and 
the non-substituted chalcone (18) was not displayed 
xanthine oxidase inhibitory activity. Moreover, the pres-
ence of hydroxyl groups at C(2′), C(4′), and C(4) plays 
an important role in the inhibition of XO (5  > 6 ≫ 4), 
these hydroxyl groups increase the activity through an 
increment in the stabilization of the aromatic ring due to 
inductive effect (Ponce et al. 2000). So, the methylation 
or acetylation of the hydroxyl groups generally decreases 
the inhibition activity (3 > 14 ≈ 15; 5 > 10 > 8 > 9 ≈ 16; 
Table 3 Optimization of parameters for the synthesis of 5
Reaction was carried out at KOH 14 M
a Using CH
b Using UA
Entry Temp. (°C) Time (h) Molar ratio
(1a/2b)
Yield (%)
1a 30 12 1:1 24.1
2a 30 24 1:1 29.2
3a 30 36 1:1 36.2
4a 30 48 1:1 38.3
5b 30 4 1:1 23.8
6b 30 5 1:1 28.4
7b 30 6 1:1 32.7
8b 30 7 1:1 36.9
9b 30 8 1:1 44.0
10b 30 10 1:1 40.8
11b 30 12 1:1 38.1
12b 60 8 1:1 47.1
13b 70 8 1:1 50.9
14b 80 8 1:1 57.1
15b 90 8 1:1 55.4
16b 80 8 1.5:1 64.3
17b 80 8 2:1 69.8
18b 80 8 2.5:1 54.2











Scheme 2 Synthesis of sappanchalcone (7). Reagent and conditions: a CH3COOH, polyphosphoric acid, 60 °C, 30 min; b 2ʹ,4ʹ-
dihydroxyacetophenone, KOH 12 M, ultrasound-assisted, 80 °C, 8 h
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6 > 12; 5 ≫ 17); the replacement of all hydroxyl groups 
in ring B (9, 15‒17) has an extreme reducing effect on 
inhibitory activity.
The presence of hydroxyl group at C(2′) may allow ring 
closure in solution, thus reducing the effective concen-
tration of the compound in its chalcone form (Beiler and 
Martin 1951). Thus, the methylation of C(2′) hydroxyl 
group causes an increase in activity (7  >  5, 11  >  10). 
However, the presence of methoxyl groups at both C(2′) 
and C(4′) increases the activity (11 > 7 > 5 > 10) due to 
the activation of the keto group by oxygens on ring A 










1d R1=OCH3, R2=OH, R3=H
1e R1=R2=OCH3, R3=H
1f R1=OCH3, R2=H, R3=OH
2b R=H, R1=R2=OH
2d R=H, R1=OCH3, R2=OH








8 R1 = R2 = OH, R3 = H, R4 = OH, R5 = OCH3
9 R1 = R2 = OH, R3 = H, R4 = R5 = OCH3
10 R1 = OCH3, R2 = OH, R3 = H, R4 = R5 = OH
11 R1 = R2 = OCH3, R3 = H, R4 = R5 = OH
12 R1 = R2 = R3 = OH, R4 = H, R5 = OCH3






3 R1 = R2 = H, R3 = R4 = OH





14 R1 = R2 = H, R3 = OH, R4 = OCH3
15 R1 = R2 = H, R3 = R4 = OCH3
16 R1 = OCH3, R2 = OH, R3 = R4 = OCH3
17 R1 = OAc, R2 = OH, R3 = R4 = OAc
Scheme 3 Synthesis of chalcone derivatives (8–17)
















Compound R1 R2 R3 R4 R5 R6 IC50 (μM)
3 H H H H OH OH 40.9
4 OH H OH H H H >100
5 OH H OH H OH OH 4.3
6 OH H OH OH H OH 16.3
7 OMe H OH H OH OH 3.9
8 OH H OH H OH OMe 36.7
9 OH H OH H OMe OMe >100
10 OH H OMe H OH OH 19.2
11 OMe H OMe H OH OH 2.5
12 OH H OH OH H OMe 21.8
13 OH Caffeoyl OMe H OH OH 2.4
14 H H H H OH OMe >100
15 H H H H OMe OMe >100
16 OH H OMe H OMe OMe >100
17 OH H OAc H OAc OAc >100
18 H H H H H H >100
Allopurinol 2.5
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Chalcones with no hydroxyl group in ring B (4) do not 
show activity. Moreover, these with two hydroxyl groups 
located at ortho- position on ring B at C(3) and C(4), 
showed stronger activity than those with the equivalent 
substitutes but located at the meta- position (5 > 6 ≫ 4). 
It is explained based on molar refractivity parameter; 
the high polarizability will enhance the attractive dis-
persion interactions with an aromatic residue of enzyme 
binding site through π–π stacking interactions (Costan-
tino et al. 1996; Mathew et al. 2015). However, when the 
C(4) hydroxyl was methylated, the above conclusion is 
reversed. That may be because the methoxyl group has a 
positive inductive effect, while the hydroxyl ones have a 
negative inductive effect.
Compound 13, a dimer-like compound of 10, showed 




All reagents were obtained at highest quality from com-
mercially available sources and were used as received. All 
compounds were elucidated by NMR and HRMS data. 
Anal. TLC: aluminum plates precoated with Merck Silica 
gel 60 F254 as an adsorbent; visualization on TLC plates 
was done with UV light. Column chromatography (CC): 
silica gel (SiO2; Kieselgel 40, 0.063–0.200  mm, Merck). 
HPLC: Agilent 1100 series coupled to IR/UV/VIS detec-
tor; a ZORBAX Eclipse Plus C18 column (particle size 
5 μm, 250 × 4.6 mm i.d.); the mobile phase, MeOH/H2O/
CH3COOH; flow rate, 0.5–1  mL  min−1; the chromato-
grams monitored at 260  nm. Ultrasonic bath: Branson 
1210E-MT ultrasonic bath, operating at 47  kHz. NMR 
Spectra: NMR Bruker Avance II 500 spectrometer (at 500 
and 125 MHz for 1H and 13C, resp.), at 25 °C; δ in ppm, J 
in Hz; HR-ESI–MS: Bruker Daltonics micrOTOF-QII; in 
m/z.
General procedure for the synthesis of chalcones in group I 
(compounds 3 and 4)
~2.0  mmol of benzaldehyde derivatives [276.2  mg of 
3,4-dihydroxybenzaldehyde (1a); 106.1  mg of benzal-
dehyde (1b)] and ~1.0  mmol of acetophenone deriva-
tives [120.2  mg of acetophenone (2a); 152.2  mg of 
2ʹ,4ʹ-dihydroxyacetophenone (2b)] were dissolved in 
1.00 mL MeOH, then 1.00 mL KOH 10 M was added. The 
flask containing the resulting mixture was suspended in 
the ultrasonic water bath at 70 °C for 6 h.
General procedure for the synthesis of chalcones in group 
II (compounds 5 and 6)
~2.0  mmol of benzaldehyde derivatives [275.9  mg 
of 3,4-dihydroxybenzaldehyde (1a); 276.3  mg of 
2,4-dihydroxy benzaldehyde (1c)] and ~1.0 mmol of 2ʹ,4ʹ-
dihydroxyacetophenone (2b) (152.1  mg) were dissolved 
in 1.00 mL H2O, then 1.00 mL KOH 14 M was added. The 
flask containing the resulting mixture was suspended in 
the ultrasonic water bath at 80 °C for 8 h.
All above reactions were monitored by thin-layer chro-
matography (TLC) with the MeOH/CHCl3 (6–10  %). 
After completion, the reaction mixtures were quenched 
by acidification with HCl 3  M to pH ~5 and cooled to 
0 °C to precipitate crude products, which were recrystal-
lized with MeOH:H2O (1:3) to afford pure chalcones.
General procedure for O‑methylation (compound 1d–f, 
2d–f, 8, 9, and 14–16)
Dissolved ~1.0 mmol of the reactants [138.2 mg of 3,4-dihy-
droxybenzaldehyde (1a); 138.1  mg of 2,4-dihydroxyben-
zaldehyde (1c); 152.4  mg of 2ʹ,4ʹ-dihydroxyacetophenone 
(2b); 241.5  mg of 3,4-dihydroxychalcone (3); 272.1  mg of 
3,4,2ʹ,4ʹ-tetrahydroxychalcone (5)] in 10.00  mL acetone, 
then added Na2CO3 (160.0  mg, 1.51  mmol). These were 
subsequently treated with CH3I in a fourfold amount cor-
responding to the moles of the hydroxyl group in the 
reactants (1.135 or 2.271  g). The mixture was stirred for 
24–36 h at room temperature. Then the reaction mixture 
was acidified with HCl 1 M and extracted three times with 
ethyl acetate (20 mL × 3). Finally, flash column chromatog-
raphy was used with EtOAc/n-hexane (20 %) to purify the 
products.
General procedure for the synthesis of O‑methylated 
chalcones (compounds 7–13)
The benzaldehyde derivatives (1a, 1d, 1e, or 1f) and the 
appropriate acetophenone derivatives (2b, 2d, 2e, or 2f) 
were dissolved in 1.00  mL H2O (except for the experi-
ment carried out with 1e or 2f, which was dissolved in 
1.00  mL MeOH), then added 1.00  mL KOH 12  M. The 
flask containing the resulting mixture was suspended in 
ultrasonic water bath at 80 °C for 8 h. The desired prod-
ucts were obtained by the following work-up: the reac-
tion mixtures were acidified with HCl 3  M to pH ~5; 
the solutions were allowed to cool slowly to 0 °C to pre-
cipitate crude products. These were recrystallized with 
MeOH:H2O (1:3) to afford pure chalcones.
3ʹ‑Caffeoyl‑3,4,2ʹ‑trihydroxy‑4ʹ‑methoxychalcone (13)
m.p. 200–201  °C. 1H-NMR (500 MHz, acetone-d6): 8.36 
(d, J  =  9.0, H–C(6ʹ)); 7.83 (d, J  =  15.3, H–C(β)); 7.76 
(d, J = 15.3, H–C(α)); 7.37 (d, J = 2.0, H–C(2)); 7.27 (d, 
J =  16.0, H–C(βʹ)); 7.23 (dd, J =  9.0, 2.0, H–C(6)); 7.16 
(d, J  =  2.0, H–C(2′′)); 7.00 (dd, J  =  9.0, 2.0, H–C(6′′)); 
6.90 (d, J = 9.0, H–C(5)); 6.84 (d, J = 9.0, H–C(5′′)); 6.79 
(d, J = 16.0, H–C(αʹ)); 6.78 (d, J = 9.0, H–C(5ʹ)); 3.89 (s, 
MeO). 13C-NMR (125  MHz, acetone-d6): 193.3; 193.1; 
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164.3; 163.5; 150.4; 149.4; 146.8; 146.6; 146.5; 146.4; 
133.4; 127.8; 127.7; 126.5; 123.9; 123.1; 118.9; 118.0; 
116.5; 116.4; 116.3; 115.8; 115.3; 108.8; 56.6. HR-ESI–MS: 
m/z 447.1072 ([M–H]−, C25H20O8; 448.1158).
General procedure for O‑actylation (compound 17)
Dissolved 50.0 mg of the compound 5 in 2.00 mL acetic 
anhydride, then added two drops of pyridine. The mix-
ture was stirred for 1 h at room temperature. Finally, the 
crude product was precipitated by water addition, which 
was purified by using flash column chromatography with 
EtOAc/CHCl3 (0–20 %).
3,4,4ʹ‑Triacetoxy‑2ʹ‑hydroxychalcone (17)
m.p. 110–111  °C. 1H-NMR (500 MHz, acetone-d6): 8.35 
(d, J = 9.0, H–C(6ʹ)); 8.06 (d, J = 15.5, H–C(β)); 7.94 (d, 
J =  15.5, H–C(α)); 7.83 (dd, J =  8.3, 2.0, H–C(6)); 7.80 
(d, J = 2.1, H–C(2)); 7.38 (d, J = 8.3, H–C(5)); 6.79 (dd, 
J  =  9.0, 2.1, H–C(5ʹ)); 6.77 (d, J  =  2.1, H–C(3ʹ)); 2.31, 
2.30, 2.29 (s, 3 AcO). 13C-NMR (125  MHz, acetone-d6): 
194.1; 169.0; 168.7; 168.5; 158.2; 157.1; 145.6; 144.5; 
144.0; 134.4; 132.9; 128.4; 125.1; 124.5; 122.6; 118.7; 
114.0; 111.7; 20.6; 20.5; 12.1. HR-ESI–MS: m/z 397.0915 
([M–H]−, C21H18O8; 398.1002).
4ʹ‑Hydroxy‑2ʹ‑methoxyacetophenone (2c)
The reaction mixture consisting of 4.012  g polyphos-
phoric acid, 0.310 g of 3-methoxyphenol (2.5 mmol) and 
0.21 mL of glacial acetic acid (3.78 mmol) was stirred at 
60–70  °C for 30  min. The crude product was extracted 
three times with ethyl acetate (20  mL  ×  3). Used flash 
column chromatography with EtOAc/n-hexane (20  %) 
to purify the product 2c, and the reaction yield was 30 %. 
Obtained 2c together with two by-products 2d and 2e.
Assessment of xanthine oxidase inhibitory activity
Briefly, the XO inhibitory activity was assayed spectro-
photometrically under aerobic conditions (Nguyen et al. 
2005). The assay mixture consisting of 50 μL of test solu-
tion, 35  μL of 70  mM phosphate buffer (pH 7.5), and 
30 μL of enzyme solution (0.01 units/mL in 70 mM phos-
phate buffer, pH 7.5) was prepared immediately before 
use. After preincubation at 25 °C for 15 min, the reaction 
was initiated by the addition of 60 μL of substrate solu-
tion (150  μM xanthine in the same buffer). The assay 
mixture was incubated at 25 °C for 30 min. The reaction 
was stopped by adding 25 μL of HCl 1 N, and the absorb-
ance at 290 nm was measured with a Shimadzu UV-1800. 
A blank was prepared in the same way, but the enzyme 
solution was added to the assay mixture after adding 
HCl 1 N. One unit of xanthine oxidase is defined as the 
amount of enzyme required to produce 1  μmol of uric 
acid/min at 25  °C. XO inhibitory activity was expressed 
as the percentage inhibition of XO in the above assay 
system, calculated as (1  −  B/A)  ×  100, where A and 
B are the activities of the enzyme without and with the 
test material. IC50 values were calculated from the mean 
values of data from four determinations. Allopurinol, a 
known inhibitor of XO, was used as a positive control.
Conclusions
It is the first research on synthesis sappanchalcone (7) by 
Claisen–Schmidt condensation. This procedure was sim-
ple and generated fewer by-products than Heck coupling 
reaction followed by demethylation (Bianco et al. 2004). 
The overall yield of this procedure was 6.6 %, higher than 
that of reported procedure (4  %) (Bianco et  al. 2004). 
Nine out of fifteen synthetic chalcones showed inhibitory 
activity (3; 5–8; 10–13). Compound 5, 7, 11 and 13 with 
IC50 values ranging from 2.4 to 4.3 μM displayed potent 
activity, comparing to allopurinol (IC50, 2.5  μM). This 
result suggests that these chalcone derivatives can be 
used as potential non-purine xanthine oxidase inhibitors. 
Structure–activity relationship was also proposed.
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